CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate.
Bocchia
M
M
Ippoliti
M
M
Gozzetti
A
A
Abruzzese
E
E
Calabrese
S
S
Amabile
M
M
Pirrotta
M T
MT
Crupi
R
R
Tozzuoli
D
D
Trawinska
M M
MM
Defina
M
M
Martinelli
G
G
Lauria
F
F
D000328:Adult; D000368:Aged; D001549:Benzamides; D001853:Bone Marrow / Q000473:pathology; D002452:Cell Count; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate